Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells

Anti-androgen therapy with Enzalutamide (Enz) has been used as a therapy for castration resistant prostate cancer (CRPC) patients after development of resistance to chemotherapy with Docetaxel (Doc). The potential impacts of Doc-chemotherapy on the subsequent Enz treatment, however, remain unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Changyi, Chou, Fu-Ju, Lu, Jieyang, Lin, Wanying, Truong, Matthew, Tian, Hao, Sun, Yin, Luo, Jie, Yang, Rachel, Niu, Yuanjie, Nadal, Rosa, Antonarakis, Emmanuel S., Cordon-Cardo, Carlos, Sahasrabudhe, Deepak, Huang, Chi-Ping, Yeh, Shuyuan, Li, Gonghui, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521536/
https://www.ncbi.nlm.nih.gov/pubmed/32920545
http://dx.doi.org/10.18632/aging.103917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521536/
https://www.ncbi.nlm.nih.gov/pubmed/32920545
http://dx.doi.org/10.18632/aging.103917

Ejemplares similares